Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 212

1.

Midazolam Pharmacokinetics in Obese and Non-obese Children and Adolescents.

Gade C, Sverrisdóttir E, Dalhoff K, Sonne J, Johansen MØ, Christensen HR, Burhenne J, Mikus G, Holm JC, Lund TM, Holst H.

Clin Pharmacokinet. 2019 Nov 19. doi: 10.1007/s40262-019-00838-1. [Epub ahead of print]

PMID:
31745864
2.

Minor contribution of cytochrome P450 3A activity on fentanyl exposure in palliative care cancer patients.

Geist MJP, Ziesenitz VC, Bardenheuer HJ, Burhenne J, Skopp G, Mikus G.

Sci Rep. 2019 Oct 10;9(1):14635. doi: 10.1038/s41598-019-51279-6.

3.

Prophylactic Use of Enoxaparin in Adolescents During Bariatric Surgery-a Prospective Clinical Study.

Vaughns JD, Ziesenitz VC, Williams EF, Nadler EP, Mikus G, van den Anker J.

Obes Surg. 2019 Aug 28. doi: 10.1007/s11695-019-04135-5. [Epub ahead of print]

PMID:
31463801
4.

Quantification of microdosed oral yohimbine and its major metabolite in human plasma in the picogram range.

Vay M, Sauter M, Mikus G, Burhenne J.

Bioanalysis. 2019 Aug;11(16):1459-1467. doi: 10.4155/bio-2019-0129. Epub 2019 Aug 14.

PMID:
31411489
5.

Simultaneous phenotyping of CYP2E1 and CYP3A using oral chlorzoxazone and midazolam microdoses.

Hohmann N, Blank A, Burhenne J, Suzuki Y, Mikus G, Haefeli WE.

Br J Clin Pharmacol. 2019 Oct;85(10):2310-2320. doi: 10.1111/bcp.14040. Epub 2019 Aug 9.

PMID:
31222796
6.

Novel insights into the complex pharmacokinetics of voriconazole: a review of its metabolism.

Schulz J, Kluwe F, Mikus G, Michelet R, Kloft C.

Drug Metab Rev. 2019 Aug;51(3):247-265. doi: 10.1080/03602532.2019.1632888. Epub 2019 Aug 16.

PMID:
31215810
7.

Microdosed midazolam for the determination of cytochrome P450 3A activity: Development and clinical evaluation of a buccal film.

Kiene K, Hayasi N, Burhenne J, Uchitomi R, Sünderhauf C, Schmid Y, Haschke M, Haefeli WE, Krähenbühl S, Mikus G, Inada H, Huwyler J.

Eur J Pharm Sci. 2019 Jul 1;135:77-82. doi: 10.1016/j.ejps.2019.05.010. Epub 2019 May 16.

PMID:
31102650
8.

Alteration of drug-metabolizing enzyme activity in palliative care patients: Microdosed assessment of cytochrome P450 3A.

Geist M, Bardenheuer H, Burhenne J, Mikus G.

Palliat Med. 2019 Jul;33(7):850-855. doi: 10.1177/0269216319843629. Epub 2019 Apr 26.

PMID:
31023150
9.

Decreased Cytochrome P450 3A activity in palliative patients with haematological diseases: Potential impact on supportive drug therapies.

Geist MJP, Siller N, Egerer G, Bardenheuer H, Burhenne J, Mikus G.

Basic Clin Pharmacol Toxicol. 2019 Aug;125(2):117-122. doi: 10.1111/bcpt.13232. Epub 2019 Apr 15.

PMID:
30916851
10.

A follow-up report on potential drug interactions with clementines: Two single case experiments show no effect on CYP3A-dependent midazolam clearance.

Hohmann N, Mikus G, Haefeli WE, Schwenger V, Gattuso G, Barreca D, Weiss J.

Eur J Pharm Sci. 2019 May 15;133:54-58. doi: 10.1016/j.ejps.2019.03.013. Epub 2019 Mar 21.

PMID:
30905614
11.

Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs.

Mikus G, Foerster KI, Schaumaeker M, Lehmann ML, Burhenne J, Haefeli WE.

Clin Pharmacokinet. 2019 Sep;58(9):1155-1163. doi: 10.1007/s40262-019-00749-1.

PMID:
30828771
12.

Probes and Cocktails for Drug-Drug Interaction Evaluation: The Future Is Microdosing?

Mikus G.

Clin Pharmacol Ther. 2019 Jun;105(6):1335-1337. doi: 10.1002/cpt.1350. Epub 2019 Feb 12. No abstract available.

PMID:
30756383
13.

Methodological Considerations on CYP2D6 Phenoconversion Due to Drug-Drug Interaction.

Ziesenitz VC, Mikus G.

Clin Pharmacol Ther. 2019 May;105(5):1076. doi: 10.1002/cpt.1336. Epub 2019 Feb 10. No abstract available.

PMID:
30739311
14.

Ketoconazole and Liver Injury: A Five-Year Update.

Greenblatt DJ, Mikus G.

Clin Pharmacol Drug Dev. 2019 Jan;8(1):6-8. doi: 10.1002/cpdd.652. No abstract available.

PMID:
30599463
15.

Obesity-induced CYP2E1 activity in children.

Gade C, Dalhoff K, Petersen T, Riis T, Schmeltz C, Chabanova E, Christensen HR, Mikus G, Burhenne J, Holm JC, Holst H.

Br J Clin Pharmacol. 2019 Feb;85(2):458-459. doi: 10.1111/bcp.13813. Epub 2018 Dec 9. No abstract available.

PMID:
30537026
16.

No alteration of voriconazole concentration by plasmapheresis in a critically ill patient.

Vay M, Foerster KI, Mahmoudi M, Seeßle J, Mikus G.

Eur J Clin Pharmacol. 2019 Feb;75(2):287-288. doi: 10.1007/s00228-018-2582-6. Epub 2018 Oct 22. No abstract available.

PMID:
30349944
17.

Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John's wort should be avoided.

Huppertz A, Werntz L, Meid AD, Foerster KI, Burhenne J, Czock D, Mikus G, Haefeli WE.

Br J Clin Pharmacol. 2018 Dec;84(12):2903-2913. doi: 10.1111/bcp.13757. Epub 2018 Oct 11.

PMID:
30192025
18.

Impact of patient education on plasma concentrations and effectiveness of posaconazole oral suspension under clinical conditions.

Geist MJP, Egerer G, Mikus G, Blank A, Hohmann N, Heinz WJ, Carls A.

Basic Clin Pharmacol Toxicol. 2019 Jan;124(1):56-61. doi: 10.1111/bcpt.13093. Epub 2018 Aug 2.

PMID:
29989301
19.

Isotopically labelled paroxetine standard allows for definite structure elucidation of the paroxetine tandem mass spectrum.

Vay M, Majewsky M, Mikus G.

Rapid Commun Mass Spectrom. 2018 Aug 15;32(15):1311-1312. doi: 10.1002/rcm.8178. No abstract available.

PMID:
29845653
20.

A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer.

Schmitz-Winnenthal FH, Hohmann N, Schmidt T, Podola L, Friedrich T, Lubenau H, Springer M, Wieckowski S, Breiner KM, Mikus G, Büchler MW, Keller AV, Koc R, Springfeld C, Knebel P, Bucur M, Grenacher L, Haefeli WE, Beckhove P.

Oncoimmunology. 2018 Jan 16;7(4):e1303584. doi: 10.1080/2162402X.2017.1303584. eCollection 2018.

21.

Higher chlorzoxazone clearance in obese children compared with nonobese peers.

Gade C, Dalhoff K, Petersen TS, Riis T, Schmeltz C, Chabanova E, Christensen HR, Mikus G, Burhenne J, Holm JC, Holst H.

Br J Clin Pharmacol. 2018 Aug;84(8):1738-1747. doi: 10.1111/bcp.13602. Epub 2018 Jun 3.

22.

Methadone against cancer: Lost in translation.

Theile D, Mikus G.

Int J Cancer. 2018 Oct 15;143(8):1840-1848. doi: 10.1002/ijc.31356. Epub 2018 Mar 23. Review.

23.

In Vivo CYP3A Activity in Palliative Care Patients: Study Protocol for a Single Arm Prospective Trial.

Geist MJP, Bardenheuer HJ, Burhenne J, Mikus G.

J Palliat Med. 2018 May;21(5):686-688. doi: 10.1089/jpm.2017.0461. Epub 2018 Jan 12.

PMID:
29327978
24.

Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature.

Meid AD, Bighelli I, Mächler S, Mikus G, Carrà G, Castellazzi M, Lucii C, Martinotti G, Nosè M, Ostuzzi G, Barbui C, Haefeli WE.

Ther Adv Psychopharmacol. 2017 Dec;7(12):251-264. doi: 10.1177/2045125317721662. Epub 2017 Aug 28.

25.

Correction to: Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review.

Ziesenitz VC, Vaughns JD, Koch G, Mikus G, van den Anker JN.

Clin Pharmacokinet. 2018 Mar;57(3):393-417. doi: 10.1007/s40262-017-0609-2.

PMID:
29178007
26.

Inhibition of human cytochromes P450 in vitro by ritonavir and cobicistat.

Hossain MA, Tran T, Chen T, Mikus G, Greenblatt DJ.

J Pharm Pharmacol. 2017 Dec;69(12):1786-1793. doi: 10.1111/jphp.12820. Epub 2017 Sep 29.

PMID:
28960344
27.

In vitro inhibition of human UGT isoforms by ritonavir and cobicistat.

Algeelani S, Alam N, Hossain MA, Mikus G, Greenblatt DJ.

Xenobiotica. 2018 Aug;48(8):764-769. doi: 10.1080/00498254.2017.1370655. Epub 2017 Sep 11.

PMID:
28891378
28.

Real-world complexity of atrial fibrillation treatment with oral anticoagulants: design and interpretation of pharmacoepidemiological studies.

Meid AD, Mächler S, Haefeli WE, Mikus G.

Br J Clin Pharmacol. 2017 Oct;83(10):2321-2324. doi: 10.1111/bcp.13348. Epub 2017 Jul 21. No abstract available.

29.

Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review.

Ziesenitz VC, Vaughns JD, Koch G, Mikus G, van den Anker JN.

Clin Pharmacokinet. 2018 Feb;57(2):125-149. doi: 10.1007/s40262-017-0569-6. Review. Erratum in: Clin Pharmacokinet. 2017 Nov 24;:.

30.

[Erratum to: Management of chronic pain using extended release tilidine : Quality of life and implication of comedication on tilidine metabolism].

Wolfert C, Merbach M, Stammler G, Emrich O, Meid AD, Burhenne J, Blank A, Mikus G.

Schmerz. 2017 Oct;31(5):515. doi: 10.1007/s00482-017-0236-8. German. No abstract available.

PMID:
28674828
31.

Acute and painful exacerbation of RLS and PLM induced by opioid interaction - withdrawal syndrome.

Högl B, Lohner H, Mikus G, Huff H.

Sleep Med. 2017 Aug;36:186-187. doi: 10.1016/j.sleep.2017.05.010. Epub 2017 May 27. No abstract available.

PMID:
28662817
32.

Intracellular vorinostat accumulation and its relationship to histone deacetylase activity in soft tissue sarcoma patients.

Burhenne J, Liu L, Heilig CE, Meid AD, Leisen M, Schmitt T, Kasper B, Haefeli WE, Mikus G, Egerer G.

Cancer Chemother Pharmacol. 2017 Aug;80(2):433-439. doi: 10.1007/s00280-017-3357-y. Epub 2017 Jun 13.

PMID:
28612091
33.

[Management of chronic pain using extended release tilidine : Quality of life and implication of comedication on tilidine metabolism].

Wolfert C, Merbach M, Stammler G, Emrich O, Meid AD, Burhenne J, Blank A, Mikus G.

Schmerz. 2017 Oct;31(5):516-523. doi: 10.1007/s00482-017-0228-8. German. Erratum in: Schmerz. 2017 Jul 3;:.

PMID:
28597312
34.

The NTCP-inhibitor Myrcludex B: Effects on Bile Acid Disposition and Tenofovir Pharmacokinetics.

Blank A, Eidam A, Haag M, Hohmann N, Burhenne J, Schwab M, van de Graaf S, Meyer MR, Maurer HH, Meier K, Weiss J, Bruckner T, Alexandrov A, Urban S, Mikus G, Haefeli WE.

Clin Pharmacol Ther. 2018 Feb;103(2):341-348. doi: 10.1002/cpt.744. Epub 2017 Jun 21.

PMID:
28543042
35.

Ultra-sensitive and selective quantification of endothelin-1 in human plasma using ultra-performance liquid chromatography coupled to tandem mass spectrometry.

Suzuki Y, Witt L, Mier W, Mikus G, Markert C, Haefeli WE, Burhenne J.

J Pharm Biomed Anal. 2017 Aug 5;142:84-90. doi: 10.1016/j.jpba.2017.04.038. Epub 2017 Apr 29.

PMID:
28500979
36.

Autoinhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics.

Hohmann N, Kreuter R, Blank A, Weiss J, Burhenne J, Haefeli WE, Mikus G.

Br J Clin Pharmacol. 2017 Sep;83(9):1954-1965. doi: 10.1111/bcp.13297. Epub 2017 May 18.

37.

Erratum to: Use of Fentanyl in Adolescents with Clinically Severe Obesity Undergoing Bariatric Surgery: A Pilot Study.

Vaughns JD, Ziesenitz VC, Williams EF, Mushtaq A, Bachmann R, Skopp G, Weiss J, Mikus G, van den Anker JN.

Paediatr Drugs. 2017 Jun;19(3):269. doi: 10.1007/s40272-017-0220-x. No abstract available.

PMID:
28303480
38.

Use of Fentanyl in Adolescents with Clinically Severe Obesity Undergoing Bariatric Surgery: A Pilot Study.

Vaughns JD, Ziesenitz VC, Williams EF, Mushtaq A, Bachmann R, Skopp G, Weiss J, Mikus G, van den Anker JN.

Paediatr Drugs. 2017 Jun;19(3):251-257. doi: 10.1007/s40272-017-0216-6. Erratum in: Paediatr Drugs. 2017 Jun;19(3):269.

39.

Semisimultaneous Midazolam Administration to Evaluate the Time Course of CYP3A Activation by a Single Oral Dose of Efavirenz.

Mikus G, Heinrich T, Bödigheimer J, Röder C, Matthee AK, Weiss J, Burhenne J, Haefeli WE.

J Clin Pharmacol. 2017 Jul;57(7):899-905. doi: 10.1002/jcph.879. Epub 2017 Feb 14.

PMID:
28194792
40.

Who is a 'healthy subject'?-consensus results on pivotal eligibility criteria for clinical trials.

Breithaupt-Groegler K, Coch C, Coenen M, Donath F, Erb-Zohar K, Francke K, Goehler K, Iovino M, Kammerer KP, Mikus G, Rengelshausen J, Sourgens H, Schinzel R, Sudhop T, Wensing G.

Eur J Clin Pharmacol. 2017 Apr;73(4):409-416. doi: 10.1007/s00228-016-2189-8. Epub 2017 Jan 7. Review.

41.

European Pain Federation position paper on appropriate opioid use in chronic pain management.

O'Brien T, Christrup LL, Drewes AM, Fallon MT, Kress HG, McQuay HJ, Mikus G, Morlion BJ, Perez-Cajaraville J, Pogatzki-Zahn E, Varrassi G, Wells JC.

Eur J Pain. 2017 Jan;21(1):3-19. doi: 10.1002/ejp.970.

42.

Clementine juice has the potential for drug interactions - In vitro comparison with grapefruit and mandarin juice.

Theile D, Hohmann N, Kiemel D, Gattuso G, Barreca D, Mikus G, Haefeli WE, Schwenger V, Weiss J.

Eur J Pharm Sci. 2017 Jan 15;97:247-256. doi: 10.1016/j.ejps.2016.11.021. Epub 2016 Nov 24.

PMID:
27890698
43.

No Increased Risk of Ketoconazole Toxicity in Drug-Drug Interaction Studies.

Outeiro N, Hohmann N, Mikus G.

J Clin Pharmacol. 2016 Oct;56(10):1203-11. doi: 10.1002/jcph.795. Epub 2016 Aug 22. Review.

PMID:
27406945
44.

Vorinostat in refractory soft tissue sarcomas - Results of a multi-centre phase II trial of the German Soft Tissue Sarcoma and Bone Tumour Working Group (AIO).

Schmitt T, Mayer-Steinacker R, Mayer F, Grünwald V, Schütte J, Hartmann JT, Kasper B, Hüsing J, Hajda J, Ottawa G, Mechtersheimer G, Mikus G, Burhenne J, Lehmann L, Heilig CE, Ho AD, Egerer G.

Eur J Cancer. 2016 Sep;64:74-82. doi: 10.1016/j.ejca.2016.05.018. Epub 2016 Jun 28.

PMID:
27367154
45.

Ultrasensitive quantification of the CYP2E1 probe chlorzoxazone and its main metabolite 6-hydroxychlorzoxazone in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry after chlorzoxazone microdosing.

Witt L, Suzuki Y, Hohmann N, Mikus G, Haefeli WE, Burhenne J.

J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Aug 1;1027:207-13. doi: 10.1016/j.jchromb.2016.05.049. Epub 2016 May 31.

PMID:
27300008
46.

Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole.

Hohmann N, Kocheise F, Carls A, Burhenne J, Weiss J, Haefeli WE, Mikus G.

Clin Pharmacokinet. 2016 Dec;55(12):1535-1545.

PMID:
27236320
47.

Treatment with rilpivirine does not alter plasma concentrations of the CYP3A substrates tadalafil and midazolam in humans.

Hohmann N, Reinhard R, Schnaidt S, Witt L, Carls A, Burhenne J, Mikus G, Haefeli WE.

J Antimicrob Chemother. 2016 Aug;71(8):2241-7. doi: 10.1093/jac/dkw125. Epub 2016 May 1.

PMID:
27141088
48.

First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B.

Blank A, Markert C, Hohmann N, Carls A, Mikus G, Lehr T, Alexandrov A, Haag M, Schwab M, Urban S, Haefeli WE.

J Hepatol. 2016 Sep;65(3):483-9. doi: 10.1016/j.jhep.2016.04.013. Epub 2016 Apr 27.

PMID:
27132172
49.

The CYTONOX trial.

Gade C, Mikus G, Christensen HR, Dalhoff KP, Holm JC, Holst H.

Dan Med J. 2016 May;63(5). pii: A5226.

PMID:
27127017
50.

CYP3A activity: towards dose adaptation to the individual.

Hohmann N, Haefeli WE, Mikus G.

Expert Opin Drug Metab Toxicol. 2016 May;12(5):479-97. doi: 10.1517/17425255.2016.1163337. Epub 2016 Mar 26. Review.

PMID:
26950050

Supplemental Content

Support Center